COL7A1 and recessive dystrophic epidermolysis bullosa: Thus, the COL7A1 therapy with replacement or correction of recombinant C7 protein for healing skin wounds in combination, e.g., with MSCs or SCsP (to obtain systemic immunomodulatory and anti-inflammatory effect), can significantly reduce the severity of RDEB, and can also increase skin resistance to the damage and improve the life quality of such patients.